-
Mashup Score: 6About The Lancet Haematology - 19 day(s) ago
About
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6About The Lancet Haematology - 26 day(s) ago
About
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Transplant without salvage: cut out the middleman - 29 day(s) ago
In this issue of The Lancet Haematology, Matthias Stelljes and colleagues1 present a compelling exploration of an approach to allogeneic haematopoietic stem-cell transplantation (HSCT) in patients at high risk of relapse or induction-refractory acute myeloid leukaemia. This concept is in stark contrast with the long-upheld orthodoxy of using varying regimens of salvage chemotherapy to induce remission or a morphological leukaemia-free state before transplantation.2 These approaches, while considered to be the standard of care in most institutions, are associated with substantial morbidity, particularly when conventional chemotherapy is used.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 48
Non-inferiority of disease control could not be shown at the 2·5% significance level. The rate of treatment success was also not statistically better for patients with remission induction. Watchful waiting and immediate transplantation could be an alternative for fit patients with poor response or relapsed acute myeloid leukaemia who have a stem cell donor available. More randomised controlled intention-to-transplant trials are needed to define the optimal treatment before transplantation for patients with active acute myeloid leukaemia.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6About The Lancet Haematology - 29 day(s) ago
About
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 57
Combination of sintilimab with P-GEMOX seems to be an active and safe first-line regimen for patients with advanced ENKTL.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6About The Lancet Haematology - 1 month(s) ago
About
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The value of anti-CD30 CAR T cells in Hodgkin lymphoma - 1 month(s) ago
The use of chimeric antigen receptor (CAR) T cells in haematological malignancies is becoming increasingly widespread, with several authorised drugs and many patients benefiting from their efficacy and manageable tolerance in the short and medium term.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease - 1 month(s) ago
The exciting therapeutic potential of nitric oxide-based pharmaceuticals is the inspiration for the work of Mark Gladwin and colleagues1 in this issue of The Lancet Haematology. When sickle haemoglobin polymerises, red blood cell deformability is compromised, resulting in haemolysis and the release of free haeme. Free haemoglobin scavenges nitric oxide, an important signalling molecule, and depletes nitric oxide precursors. This nitric oxide depletion paralyses vasodilatory mechanisms and contributes to the activation of platelets, leukocytes, and endothelial cells,2 and might affect some of the devastating complications associated with sickle cell disease.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Riociguat was safe and had a significant haemodynamic effect on systemic blood pressure. The results of this study provide measures of effect and variability that will inform power calculations for future trials.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
Attending #ASH23? Emma Cookson, Senior Editor, invites you to reach out with enquiries. Explore our scope, reach & impact, commitment to publishing excellence, & more: https://t.co/iMVZeaHqrf https://t.co/UNMLek9Tuf